ScreenerHero

TPST Tempest Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tempesttx.com
0.7875USD-0.64%Mkt Cap: 13.30M $P/E: —

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of pero…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap13.30M USD
Enterprise Value19.36M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.26M USD
Revenue/Share—
Last Price0.7875 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.65
PEG—
EV/EBITDA-0.90
EV/Revenue—
P/S—
P/B13.82
EPS (TTM)-3.97
EPS (Forward)-1.21
52W Range
0.75340% of range12.23
52W High12.23 USD
52W Low0.7534 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-393.85%
ROA-155.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.82M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-116.62%
Net Debt6.78M USD
Net Debt/EBITDA-0.32
Balance Sheet
Debt/Equity1.22
Current Ratio0.38
Quick Ratio0.17
Book Value/Sh0.06 USD
Cash/Share0.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateDec 10, 2018
Splits
Last Split1:13
Split DateApr 9, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.000 USD
Upside (mean)+788.9%
Target Range7.000 USD – 7.000 USD
# Analysts1
Ownership
Shares Out.16.89M
Float11.07M
Insiders30.07%
Institutions27.98%
Short Interest
Short Ratio0.2d
Short % Float4.36%
Short % Out.2.12%
Shares Short350.42K
Short (prev mo.)373.78K
Technical
SMA 500.9598 (-18.0%)
SMA 2001.722 (-54.3%)
Beta-1.71
S&P 52W Chg16.45%
Avg Vol (30d)4.05M
Avg Vol (10d)838.05K
Technical Indicators
RSI (14)39.5
MACD-0.0542
MACD Signal-0.0494
MACD Hist.-0.0048
BB Upper1.052 USD
BB Middle0.8686 USD
BB Lower0.6853 USD
BB Width42.21%
ATR (14)0.1018 USD
Vol Ratio (20d)0.04x